QVQ to license AMC’s antibodies against BMPs for imaging purposes

AMC and QVQ, a company based in Utrecht developing custom made single domain antibodies from llama, started collaborating in 2010 on the development of antibodies against Bone Morphogenic Proteins (BMPs). The resulting compounds were patented by AMC (PCT/NL2014/050632) in 2014, with potential applications in treatment of several types of cancer, imaging and research.

Now, AMC and QVQ have entered into a license agreement allowing QVQ to commercialize these antibodies, including those against the BMP receptor, for imaging applications, while AMC still maintains the rights to the therapeutic and research applications.

Picture: imaging of BMP4 in a mouse esophagus-cancer model.